secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0001770787-24-000035
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics Q1: revenue up 5% to $141M, net loss widens to $59.9M; guidance reaffirmed
--------------------------------------------------------------------------------

- Revenue of $141.0M (+5% YoY); gross margin 66% vs 73% due to product mix shift to Xenium instruments.
- Net loss widened to $59.9M from $50.7M; operating loss $61.5M vs $52.0M.
- FY2024 revenue guidance maintained at $670M-$690M, representing 8-12% growth over FY2023.
- Shipped Visium HD for spatial discovery, GEM-X single cell technology, and Xenium cell segmentation products.
- Operating expenses up 3% to $154.4M; stock-based compensation declined to $36.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078724000035/0001770787-24-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078724000035/txg-20240430.htm
  HTML page:      https://secwatch.observer/filing/0001770787-24-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer